Celldex Therapeutics (CLDX) Current Leases (2019 - 2026)

Celldex Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Current Leases fell 2.27% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 2.27% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, up 6.89% from the prior year.
• Current Leases eased to $1.5 million in Q1 2026 per CLDX's latest filing, from $1.6 million in the prior quarter.
• Across five years, Current Leases topped out at $1.8 million in Q1 2022 and bottomed at $1.4 million in Q3 2024.
• The 5-year median for Current Leases is $1.5 million (2023), against an average of $1.5 million.
• Biggest YoY gain for Current Leases was 31.34% in 2022; the steepest drop was 17.24% in 2022.
• Year by year, Current Leases stood at $1.4 million in 2022, then increased by 11.7% to $1.6 million in 2023, then decreased by 10.04% to $1.5 million in 2024, then rose by 6.89% to $1.6 million in 2025, then declined by 5.61% to $1.5 million in 2026.
• Per Business Quant, the three latest CLDX Current Leases figures stand at $1.5 million (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025).